Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: Pharmacol Biochem Behav. 2018 Nov 9;176:16–22. doi: 10.1016/j.pbb.2018.11.002

Figure 3:

Figure 3:

Repeated lorcaserin injections interacting with chronic nicotine infusion, affect rates of nicotine self-administration. The weeks listed are weeks of drug treatment with four weeks of chronic nicotine infusion (Week 1 through resumption) and three weeks of lorcaserin injections (Week 2 through resumption). Average infusions per session refer to the average number of nicotine infusions delivered per 60-min self-administration session with each treatment condition. Results from nicotine self-administration sessions, averaged over week-long periods of the experiment (weeks 1 and 2 of continued nicotine access (1 and 2), resumed access (Res) and post-treatment (Post), grouped by treatment condition. Chronic continuous nicotine infusions (4 weeks at 0 or 2.5 mg/kg/day) and chronic s.c. lorcaserin (4 weeks at 0 or 0.6 mg/kg) injection effects on IV nicotine self-administration, weekly average response for the entirety of the experiment. Data represent mean ± sem, N=11-15/treatment